Definium Therapeutics, Inc.
NASDAQ:DFTXBiotechnology
-$0.41 today
- Market cap
- $3.99B
- Beta
- 2.38
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.18
Volume 1.91M
Average 2.67M
DFTX Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Net Margin history
Percent of revenue · from the income statement
No Net Margin data reported for this period type.
Net Margin vs competitors
How DFTX compares with its peers on the latest reported figures
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | -24.7% | +25.2 pp | +345.3 pp | |
| FY2025 | -223.4% | +252.4 pp | +27.4 pp | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | -536.4% | — | — |
DFTXDefinium Therapeutics, Inc. | FY2025 | — | — | — |
| FY2025 | — | — | — | |
LBRXLB Pharmaceuticals Inc Common Stock | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | FY2025 | — | — | — |
| Peer median (excluding DFTX) | -223.4% | +138.8 pp | +186.3 pp | |
Competitors are the stored peer set for DFTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 3.16M | 527K | 0 |
| Gross Profit | 0 | 0 | (3.16M) | (527K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 34.79M | 36.17M | 48.96M | 65.3M | 117.67M |
| Selling, General & Admin | 59.07M | 30.16M | 41.74M | 38.62M | 48.64M |
| Operating Expenses | 93.85M | 66.33M | 90.7M | 103.39M | 166.31M |
| Depreciation & Amortization | 2.62M | 3.18M | 3.16M | 527K | 0 |
| EBITDA | (91.22M) | (52.12M) | (92.57M) | (105.87M) | (178.31M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (93.85M) | (66.33M) | (93.87M) | (103.92M) | (166.31M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 1.5M | 5.58M | 11.56M | 10.96M |
| Interest Expense | 359K | 1.5M | 920K | 2.28M | 5.48M |
| Other Income / Expenses | (339K) | 9.54M | (1.87M) | (4.76M) | (17.48M) |
| Income Before Tax | (94.19M) | (56.8M) | (95.73M) | (108.68M) | (183.79M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (1.16M) | 0 | 0 | 0 | 0 |
| Net Income | (93.04M) | (56.8M) | (95.73M) | (108.68M) | (183.79M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (3.40) | (1.53) | (2.44) | (1.54) | (2.06) |
| EPS (Diluted) | (3.40) | (1.53) | (2.44) | (0.15) | (2.06) |
| Weighted Avg Shares | 27.38M | 30.86M | 39.16M | 70.46M | 89.33M |
| Weighted Avg Shares (Diluted) | 27.38M | 30.86M | 39.16M | 704.61M | 89.33M |
Definium Therapeutics, Inc.
NASDAQ:DFTX
Intrinsic Alpha fair value
Locked
Current Price
$29.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.